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Abstract
If IPD is available for some or all trials in an NMA, then incorpo-
rating this IPD into an NMA is routinely considered to be preferable.
However, the situation often arises where a researcher has IPD for
trials concerning a particular treatment (for example from a spon-
sor), but none for other trials. Therefore, one can reweight the IPD
so that the covariate characteristics in the IPD trials match that of
the aggregate data (AgD) trials, using a Matching Adjusted Indirect
Comparison (MAIC).
We assess the impact of using the reweighted aggregated data, ob-
tained by the MAIC, in a Bayesian NMA for a connected treatment
network. We apply this method to a network of multiple myeloma
treatments in newly diagnosed patients (ndMM), where the outcome
is progression free survival. We investigate the reliability of the meth-
ods and results through a simulation study. The ndMM network con-
sists of three IPD studies comparing lenalidomide to placebo (Len-
Placebo), one AgD study comparing Len-Placebo, and one AgD study
comparing thalidomide to placebo (Thal-Placebo). We therefore in-
vestigate two options of weighting the covariates: 1. all three studies
are weighted separately to match the AgD Thal-Placebo trial. 2. pa-
tients are weighted across all three IPD studies to match the AgD
Thal-Placebo trial, but the NMA considers each trial separately.
We observe limited benefit to MAIC in the full network population.
While MAIC can be beneficial as a sensitivity analysis to confirm
results across patient populations, we advise that MAIC is used and
interpreted with caution.
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Glossary




AB-IPD trial Trial with individual patient data comparing treatment
A to treatment B.
BC-AgD trial Trial with aggregate data only comparing treatment B
to treatment C.
Ylk(AB) Outcome for patient l on treatment k in the AB trial.
Nk(AB) Number of patients assigned to treatment k in the AB
trial.
wlk Weight assigned to the patient l receiving treatment k.
Tijl time-to-event for individual l, in study i and arm j.
Cijl Censored time for individual l, in study i and arm j.
βm,tij Coefficient for the effect of covariate m for the treat-
ment in arm j of study i when the covariate is an effect
modifier.
βm Effect of covariate m for all treatments when the covari-
ate is a prognostic variable.
xm,ijl Binary indicator for the presence of the characteristic m
for patient l in arm j of study i.
xm1m2 Proportion of the population possessing the relevant
characteristics in the case of two covariates.
µi Baseline risk in trial i.
δij Study-specific treatment effect in the j
th arm of the ith
trial.
dk True effect of treatment k relative to the reference treat-
ment.
dtij True effect of the treatment in the j
th arm of the ith trial
relative to the reference treatment.
db True effect of the reference treatment.
Hik Hazard ratio of treatment k versus the baseline treat-
ment in study i.
rei,k Random effect deviation for arm k of study i.
Sij(t) Survival function for the j
th arm of the ith trial at time
t.
β0i Covariate effect in trial i when using an IPD model.
σδ Standard deviation of study-specific treatment effects.
Q Number of simulations.
M Number of covariates.3
This article is protected by copyright. All rights reserved.
1. Introduction
Network Meta Analysis (NMA) is a method for assessing the entire evidence
base for a particular disease when three or more treatment options are avail-
able1. NMA is an extension of traditional pair-wise Meta Analysis (MA),
which is used when directly evaluating two treatment options. NMA com-
bines direct and indirect evidence to obtain effect estimates comparing all
treatments against all other treatments in the network.
If IPD is available for some or all trials in an NMA, then incorporating
this IPD into an NMA is routinely considered to be a preferable form of
evidence synthesis, as it allows a more in-depth analysis of the data, and
accounts for differences in covariates between trials. However, the situation
can often arise where a researcher has IPD for trials concerning a particular
treatment (for example from a sponsor), but none for other trials. In this
case one can reweight the IPD so that the covariate characteristics in the
IPD trials match that of the aggregate data (AgD) trials, in what is known
as a matching adjusted indirect comparison (MAIC)2,3. MAIC allows one to
account for the differences in covariates between trials, and provides insight
into the potential outcome of the researcher’s IPD trial, if it had been carried
out in the trial population to which it is being matched. However, there are
many potential downsides to this method. MAIC, as currently implemented,
can potentially be open to bias or even manipulation, due to the subjective
nature that can be involved in identifying covariates for matching. Given that
this is an increasingly popular method, it is important to be able to identify
situations when it is appropriate and situations when it is not appropriate.
This importance is also expressed in Phillippo et al4, as they identify the
need for comprehensive simulation studies to explore the properties of the
method.
We undertake an MAIC for a connected network of treatments for mul-
tiple myeloma in newly diagnosed patients (ndMM) post-Autologous Stem
Cell Transplant (ASCT), where the outcome is progression-free survival. The
results of this MAIC (i.e. the aggregated data of each reweighted IPD study)
are then treated as data in a Bayesian NMA. We investigate the reliability
of the methods and results through a simulation study, which mirrors the
ndMM network. MAIC can be carried out using a number of different out-
come models. Tremblay et al, Van Sanden et al, and Kähnast et al5–7 have
all used survival models, with Van Sanden et al also using the reweighted
MAIC data in a Bayesian setting. Kähnast et al evaluate the use of MAIC
using two studies in a simulation study in a frequentist setting and found
MAIC to be particularly useful when effect modifiers are present in dissimi-
lar populations. Belger et al8 conducted a simulation study with more than
4
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two studies in a frequentist setting using a continuous outcome. We extend
these works to a Bayesian NMA with a time-to-event outcome, while also
assessing the options available when we have multiple IPD studies.
This paper aims to quantify the impact of reweighting IPD studies before
running an NMA in a Bayesian setting with a time-to-event outcome. A
simulation study is carried out to:
1. Quantify the effect of MAIC in NMAs using a hazard ratio (HR) model.
2. Investigate two different options of weighting covariates. Firstly, within
separate IPD trials, or secondly, using one weighting method across all
IPD trials.
We compare the results of the MAIC method to using a standard NMA,
and to using a mixed AgD/IPD model, which allows us to incorporate extra
information about the covariates of interest directly in the model.
This paper is organised as follows: Section 2 describes the model develop-
ment, construction of the simulation study, and the ndMM network. Section
3 presents the results of both the simulation study and the ndMM network.
A general discussion and some recommendations are provided in Section 4.
2. Methods
In this section we will describe the method of MAIC, an application to ndMM
and details of the simulation study. As a number of different models are
implemented, we describe the details of the NMA models at the end in Section
2.4.
2.1 Matching Adjusted Indirect Comparison
In this paper we consider binary covariates only. Suppose we have an AB-
IPD trial with IPD comparing treatment A to treatment B, and a BC-AgD
trial with aggregate data only comparing treatment B to treatment C. To
match to the target (BC-AgD) trial we reweight the IPD trial such that
the proportion of patients possessing the characteristic associated with each
covariate in the IPD trial match the proportion of patients possessing the
characteristic associated with each covariate in the target trial. The outcome
5
This article is protected by copyright. All rights reserved.









where the weight wlk assigned to the patient l receiving treatment k is equal
to the odds of being enrolled in the BC trial versus the AB trial, Ylk(AB) is the
outcome for patient l receiving treatment k in the AB-IPD study and Nk(AB)
is the number of patients assigned to treatment k in the AB-IPD study. For
further information see Phillippo et al4. The standard error for the MAIC
estimates is calculated by using a robust estimator in the cox proportional
hazards model, by including a cluster term for the weights.
This method may be appropriate when the effect of the treatment is
dependent on the characteristic that the patient possesses. In this case the
covariate is an effect modifier, which means there is a non-zero covariate-
treatment interaction. When the covariate-treatment interaction is zero this
means the covariate is a prognostic variable and it is not recommended to
adjust for these types of variables4 in a connected network (also known as an
anchored comparison), due to the unnecessary increase in variance associated
with MAIC.
2.2 Applied Example in Newly Diagnosed Multiple Myeloma
The ndMM network consists of three IPD studies comparing Lenalidomide to
Placebo/Observation (Len-Placebo), one AgD study comparing Len-Placebo,
and one AgD study comparing Thalidomide to Placebo (Thal-Placebo)9–13.
Figure 1 shows the network diagram.
IPD information was available for the following binary covariates:
• Age: < 60 vs ≥ 60.
• International Staging System (ISS) stage: I/II vs III.
• Adverse Risk Cytogenetics: Present vs Absent.
• Response post-ASCT (Response): Complete Response/Very Good Par-
tial Response (CR/VGPR) vs Other.
• Gender: Male vs Female.
To ascertain which covariates were effect modifiers and which were prog-
nostic variables we compared models assuming identical, exchangeable or
independent covariate-treatment interactions14 using the DIC. It has been
6
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Figure 1: Newly diagnosed multiple myeloma network. Abbreviations: IPD = in-
dividual patient data; AgD=aggregate data; Len=lenalidomide; Thal=thalidomide.
shown that it can be difficult to distinguish between models using AgD
alone15. Consequently, we used IPD models to aid in this decision-making.
In some cases, studies were missing patient level covariate information for a
proportion of the patients in the study. In this case we imputed the missing
covariate information by conditioning on the other covariates.
As there are multiple IPD studies comparing Lenalidomide to Placebo/Observation,
there are two different reweighting options:
1. MAIC Separate Trials: The IPD within each of the three studies are
reweighted such that the AgD of each reweighted study matches the
AgD trial as follows:
(a) Within each IPD study reweight the IPD, such that the propor-
tion of patients possessing the characteristic associated with each
covariate in each IPD study matches the Thal-Placebo study.
(b) Generate aggregate data from each reweighted IPD study.
(c) Combine the aggregate data from the reweighted Len-Placebo
studies and the AgD studies using NMA.
2. MAIC Pooled Trials: All IPD studies are pooled together for the
reweighting element, such that the AgD of the studies combined matches
the AgD trial, but they are put into the NMA as separate trials as fol-
lows:
(a) Pool IPD from the three IPD studies together.
(b) Reweight the IPD irrespective of study, such that the IPD from
the three studies combined matches the Thal-Placebo trial.
(c) Separate the reweighted IPD back into the three original studies.
(d) Generate aggregate data from each reweighted IPD study.
7
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(e) Combine the aggregate data from the reweighted Len-Placebo
studies and the AgD studies using NMA. Note that this contrasts
with a naive pooling approach where studies are not separated out
again before the NMA.
We wish to stress the importance of including the reweighted studies in the
NMA as separate studies in both methods to ensure the original randomisa-
tion is still intact. Note that MAIC pooled trials is a less stringent require-
ment than MAIC separate trials, as only the combination of three studies
need to reflect the covariate distribution of the AgD study, rather than each
study having to reflect the covariate distribution of the AgD study, as is
the case for MAIC separate trials. For all models when carrying out the
NMA we included all five studies. These are the three IPD Len-Placebo
trial (reweighted in the case of MAIC), the AgD Len-Placebo trial, and the
AgD Thal-Placebo trial. When carrying out the MAIC, although we could
plausibly match the IPD trials to the AgD Len-Placebo trial, in this case we
are assuming that the population of interest is the Thal-Placebo trial. The
NMA was carried out using Markov Chain Monte Carlo (MCMC) simulation
in the OpenBUGS package16.
The proportion of patients possessing the characteristic associated with
each covariate in each trial is detailed in Table 2. In order to decide which
covariates we should adjust for, we obtained an estimate for the extent of
bias from each covariate, as recommended in Phillippo et al4. We calculated
the difference in the covariate-treatment interaction for lenalidomide versus
thalidomide from the fixed effect IPD models. We also calculated the degree
of imbalance for which we need to adjust, by calculating the difference in the
proportion of the patients possessing the characteristic associated with the
covariate in the Thal-Placebo trial (Morgan), versus the average proportion
of patients possessing the characteristic associated with the covariate in the
Len-Placebo IPD trials. The imbalance of each covariate is multiplied by
the difference in the covariate-treatment interaction for lenalidomide versus
thalidomide to obtain the bias. These results are shown in Table 4.
2.3 Simulation Study
A simulation study was carried out in order to assess the impact of using
MAIC. Results were assessed by examining:
1. the mean absolute error (MAE) between the estimated effects and the
true simulated effects.
2. the posterior SD, as reported in the JAGS output.
3. the effect on the estimate of the between study heterogeneity, i.e. the
8
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Table 2: Proportion of patients with the characteristic associated with each covari-
ate in each of the Len-Placebo IPD trials and the Thal-Placebo AgD “target” trial
in the newly diagnosed multiple myeloma network for patients post-autologous stem
cell transplant. All trials compared an active treatment to placebo. For trials with
IPD, covariates are computed from the available data, which includes some missing





Age: <60 ISS Stage: III Response: CR/VGPR Cytogenetics: Present Gender: Male
Treat- Placebo Treat- Placebo Treat- Placebo Treat- Placebo Treat- Placebo
ment ment ment ment ment
McCarthy Len 0.57 0.58 0.26 0.22 0.61 0.71 - - 0.52 0.56
Attal Len 0.64 0.63 0.22 0.17 0.59 0.58 0.17 0.10 0.55 0.59
Palumbo Len 0.64 0.74 0.12 0.14 0.40 0.38 0.40 0.32 0.48 0.60
Morgan Thal 0.56 0.60 0.31 0.36 0.75 0.72 0.39 0.46 0.63 0.66
estimate of the difference in the relative treatment effects between tri-
als.
4. the coverage probability, which is the proportion of the time that the
CrI contains the true effect.
5. the bias and standard error (shown in the appendix).
Four trials were simulated. Three of these trials were IPD trials com-
paring treatment A to treatment B (AB-IPD trials), and the fourth trial
compared treatment B to C, with only the AgD available for the NMA (BC-
AgD trial). This was set up to mimic the ndMM network. However we did
not include any AB-AgD trial as this could dilute the effect of the MAIC, thus
making it more difficult to analyse the results of the simulation study and to
understand the true effect of MAIC. The network diagram for the simulation
study is shown in Figure 2. We varied the covariate-treatment interaction
(scenario 1) and the distribution of covariates in the trials (scenarios 2-4) as
detailed below. Monte Carlo error was examined and is illustrated on the
graphs in Section 3.1. The accuracy and precision of our model’s estimate of
the treatment effect was assessed as the parameters varied. The simulation
study was run in the JAGS software package17, rather than OpenBUGS, as it
was carried out through a high performance computing cluster, which better
supports JAGS.
Results from the following simulations (on the log hazard ratio scale) are
presented:
• The baseline risk in each study, the treatment effect and the overall co-
variate effect were simulated at fixed quantiles from N(0.7, 0.4). These
values were then assigned to a particular study, treatment or covariate
at each iteration. For scenario 3 (explained further in Table 3) addi-
tional results are presented in the appendix, where these parameters
9
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Figure 2: Network diagram for simulation study. Abbreviations: IPD = individual
patient data; AgD=aggregate data.
are simulated from N(1.2, 0.7) and N(0.2, 0.1).
• The mean of the covariate-treatment interaction was set to 1.2 and the
SD was varied from 0-0.8. When this was set to zero it means that the
treatment effect was the same for all levels of the covariate (or, in this
case of a binary covariate, the treatment effect is the same regardless
of whether or not the patient possesses the characteristic associated
with the covariate), i.e. the covariate is a prognostic variable. Any
other value for the standard deviation (SD) means that the treatment
has a differing effect depending on whether the patient possesses the
characteristic associated with the covariate or not, i.e. the covariate
is an effect modifier. For simulations where this is not varied this
value was set to 0.8. This means that two standard deviations of the
covariate-treatment interaction range from 0.17-0.83 on the probability
scale, which we believe sufficiently covers the difference in effect that a
covariate could plausibly have on a range of treatments.
• When the covariate-treatment interaction was varied (scenario 1), the
simulation set-up mimicked the number of patients in each trial and
the proportion of those patients possessing the characteristics associ-
ated with the covariates in the ndMM network Section 2.2. We included
three covariates; ISS stage, response, and age. We excluded cytogenet-
ics as this was not recorded in the McCarthy trial.
• For scenarios where we varied the proportion of patients possessing
the characteristics associated with the covariates (scenarios 2-4) we
considered only two covariates for simplicity. These are detailed in
Table 3. The covariates have the same proportion in each trial arm.
However, these are assigned to patients individually.
• For scenarios 2-4 the number in each IPD arm was set to 200, and the
10
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number in each AgD arm was set to 240. These figures were similar to
the numbers in the ndMM network, when the total number of patients
in AB-IPD trials was averaged over the three trials.
Any parameter that was static in a scenario was only simulated at the be-
ginning of each loop and held constant until all data points in the loop had
been sampled, in order to reduce variance between the data points.
Table 3: Proportion possessing the characteristic associated with the binary co-
variate in each arm for the simulation study. The parameters were sampled in a
loop in the range detailed below at the specified increments. Parameters where the
increments are static are fixed for that scenario. The values in scenarios 2 and 3
were chosen so that the fixed proportions were in the centre of the considered range.
The values in Scenario 4 were chosen to allow the average proportion possessing
the characteristic associated with the covariate to differ sufficiently between the


























The time-to-event (Tijl) for each individual l, in study i and arm j, was
simulated by Tijl ∼ Exp(λijl) where the rate λ is given by:
ln(λijl) = µi + dtij + β1,tij(x1,ijl) + β2,tij(x2,ijl),
where µi is the study effect in trial i, dtij is the treatment effect in arm j of
study i, and the effect of covariate 1 is given by β1,tij(x1,ijl), where β1,tij is
the covariate interaction with the treatment in arm j of study i, and x1,ijl
indicates whether patient l in arm j of study i possesses the characteristic
associated with covariate 1. The same notation follows for covariate 2. In
order to imitate a real world trial, censoring time was simulated by Cijl ∼
Unif(0,max(Ti)). Whether or not an individual was censored was decided by
the minimum of time-to-event or censoring.
Five models were tested to assess how well they predicted the true treat-
ment effects. These were:
11
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a. Standard NMA Model: Unadjusted weights.
b. Standard NMA Model with Covariate: Including a term for the average
covariate per arm in the model. In this model we only use aggregate
data and assume that the covariate is a prognostic variable due to
limited data points.
c. MAIC Separate Trials: The IPD within each of the three studies are
reweighted such that the AgD of each reweighted study matches the
AgD trial.
d. MAIC Pooled Trials: All IPD studies are pooled together for the
reweighting element, such that the AgD of the studies combined matches
the AgD trial, but they are put into the NMA as separate trials.
e. Mixed AgD/IPD Model: IPD is used in the model where possible, (i.e.
for the AB IPD trials), and we use AgD otherwise (i.e. for the BC AgD
trial). We also model each covariate as an effect modifier, assuming an
independent interaction between each treatment and covariate.
The models were tested to assess how well they predicted the true treat-
ment effects. A burn-in of 20 000 iterations was tested for convergence by
checking if the Gelman-Rubin statistic18 was less than 1.1. Following this
another 10 000 iterations were sampled for our estimates. If the convergence
condition was not met the number of iterations was doubled (both for the
burn-in and for the samples for estimation), and then tested again until the
Gelman-Rubin statistic was less than 1.1. If the chains had not converged
after a burn-in of 320 000 the corresponding simulation was excluded from
the analysis. If the chains did not converge for one of the models in a partic-
ular simulation, or if there were numerical problems, for example, if a trap
error was reported in JAGS, the results for all other models compared in the
simulation, and all other data points in the loop were excluded, in order to
eliminate any potential bias due to differing simulations. Approximately less
than 5% of simulations could not be used for each scenario for these reasons.
The accuracy of the estimate was assessed by looking at the mean absolute
error (MAE) between the estimates and the true values for treatments B
and C. It was necessary to adjust for differing levels of covariates due to
the interaction with the treatments. Given a population with M binary
covariates, there are 2M distinct covariate groups. For illustrative purposes
we consider a population with 2 covariates, for example, age (< 60 vs ≥ 60)
and ISS stage: I/II vs III. Let xm1m2 denote the proportion of the population
in each covariate group. In this case m1 is either a 1 to indicate that a patient
is under 60, and 0 otherwise. Likewise, m2 is either a 1 to indicate that a
patient has ISS stage III, and 0 if a patient has ISS stage I or II. Thus, there
are four distinct groups: x00 for patients ≥ 60 with ISS stage I or II, x10 for
12
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patients < 60 with ISS stage I or II, x01 for patients ≥ 60 with ISS stage
III, and x11 for patients < 60 with ISS stage III. The true average efficacy of
treatment k is estimated as:
d̄k = dkx00 + (dk + β1,tk)x10 + (dk + β2,tk)x01 + (dk + β1,tk + β2,tk)x11. (1)
Then, the MAE for each treatment is given by:
MAE(d̂k) ≡
∑Q
q=1|d̄kq − d̂kq |
Q
,
where d̂k is our model’s estimate of the effect of treatment k relative to treat-
ment A, and Q is the total number of simulations. Treatment A is treated as
our reference treatment and hence set to 0 for the inference, therefore results
are presented for treatments B and C only. We consider two populations of
interest:
1. Full network population: xm1m2 is computed across all studies in the
network, weighted by sample size. Although this may not necessarily be
the general population of patients in the target indication, we consider
this to be the best possible estimate for the general population.
2. Target study population: xm1m2 is computed using only the target
study.
Uncertainty is measured as the posterior SD, as reported in the JAGS out-
put. This is the same for both the full network population and the target
population. For the MAIC it is obtained in the same way as the rest of the
models, as the posterior SD in the JAGS output from the NMA using the
reweighted trial data as the input. However, the inputs for the individual
reweighted studies in the NMA have been updated to reflect that the data
has been reweighted, as detailed in Section 2.1. For the mixed AgD/IPD
model, given that we have estimated a treatment effect and an effect for
each covariate, we also use equation 1 to compute the estimate of the overall
treatment effect for that population. Note that this cannot be done for the
standard NMA models with the covariate, (Models b. and ??), as in this
case we are assuming that the covariate is a prognostic variable. For the
AgD/IPD model the calculation is carried out in the JAGS model itself, in
order to obtain the correct posterior SD and upper and lower CrI bounds
from the trace.
2.4 NMA Models
We used the HR part of a model detailed in Woods et al19 for the standard
NMA model as well as the two models after the MAIC adjustment in the
13
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simulation study (Models a., c., and d.):
ln(Hik) = µi + dk − db + reik − reib,
where Hik is the hazard ratio of treatment k versus the baseline treatment
in study i, µi is the study effect of study i, dk and db are the treatment
effects for treatment k and the baseline treatment in each study, respectively,
and rei,k is the random effect deviation for arm k of study i. The prior
distributions chosen are µi ∼ N(0, 1002), dk ∼ N(0, 1002), reik ∼ N(0, σ2),
and σ2 ∼ Unif(0, 5). σ is the measure of between study heterogeneity. All
simulated and ndMM trials had exactly two arms so corrections for multiple
arms did not need to be considered.
An extra model allowing for an extra term for each covariate was also
considered (Model b.):
ln(Hik) = µi + dk − db +
M∑
m=1
βm(xmb − xmk) + reik − reib,
where βm is the effect of each covariatem, xmb is the proportion possessing the
characteristic associated with the covariate m in the baseline arm, and xmk is
the proportion possessing the characteristic associated with the covariate m
in the treatment arm. As AgD models contain very little information about
covariates, it was not possible to assign the vague priors, which were given
the other parameters, to each βm. Therefore the prior on each βm follows
N(0, 3.162). We explore this model as it may be a feasible alternative to
MAIC, if a researcher does not have access to IPD.
We also considered a mixed AgD/IPD model to utilise IPD where possible
and AgD otherwise. This was based on similar models used by Donegan et
al14 and Saramago et al20. For the AgD part the model is:
Sij(t) =
{
1− exp(−t exp(µi)) if j=1
1− exp(−t exp(µi + δij + (βtij − βti1)xij)) if j>1
,
and for the IPD part the rate λ is given by:
ln(λ) =
{
µi + β0ixijl if j=1
µi + β0ixijl + δij + (βtij − βti1)xijl if j>1
.
For the IPD dataset we can also include the trial-specific covariate effect
β0i . In this case, βtij is the covariate effect for the treatment in the j
th arm
of the ith trial, i.e., the covariate is an effect modifier as it interacts with
each treatment differently. This covariate effect can either be modelled as
14
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independent, (i.e., each βk ∼ N(0, 1.832), where k represents the treatment),
or as exchangeable, (i.e., the distribution for each β is βk ∼ N(µβ, σ2β), with
µβ ∼ N(0, 1.832) and σβ ∼ Unif(0, 5)). β1 is set to zero, with all other
covariate effects estimated relative to the covatiate effect of treatment 1, in
order to aid convergence.




1− exp(−t exp(µi)) if j=1
1− exp(−t exp(µi + δij + βxij)) if j>1
,
and for the IPD part the rate λ is given by:
ln(λ) =
{
µi + β0ixijl if j=1
µi + β0xijl + δij + βxijl if j>1
.
Finally, we considered a model which assumes each covariate is partly an
effect modifier and partly a prognostic variable:
Sij(t) =
{
1− exp(−t exp(µi)) if j=1
1− exp(−t exp(µi + δij + βxij + (βtij − βti1)xij)) if j>1
,
and for the IPD part the rate λ is given by:
ln(λ) =
{
µi + β0ixijl if j=1
µi + β0ixijl + δij + βxijl + (βtij − βti1)xijl if j>1
,
where parameters are defined as before.
For the ndMM example we compare the three mixed AgD/IPD models
above (i.e. assuming an effect modifier, assuming prognostic variable and
assuming both) for each covariate to identify the nature of each covariate.
We also extend the mixed AgD/IPD model to using two or three covariates
where applicable in both the simulation study and the ndMM example. In
this case we assume an independent treatment effect for each covariate.
All above models can be simplified to an FE model, by removing the
re term. When identifying the nature of the covariates using the mixed
AgD/IPD models we used the FE models in order to reduce variance and
detect true interactions. Given that the goal of MAIC is to reduce differences
between studies, FE models could also be considered appropriate. However,
while MAIC may reduce some heterogeneity there is no guarantee that it has
removed all heterogeneity. For example, researchers may not have collected
all relevant covariates when carrying out the study. In the ndMM example
we know that we have not matched on cytogenetics and we have lost some
information due to the fact that age was dichotomised. Therefore, we have
assessed the suitability of both FE models and RE models.
15
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3. Results
3.1 Simulation Study
In this section we compare the models in terms of MAE in both the full
network population (i.e. all studies in the network) and the target population
(i.e. just the B vs C study in this case). The coverage probabilities associated
with these estimates are also presented. We also consider the posterior SD,
which applies to both populations. The dotted lines around each MAE and
posterior SD estimate represent the MC Error on each side. Finally, we
provide the average measure of heterogeneity for each data point. Bias and
standard error are shown in the appendix.
3.1.1 Covariate-Treatment Interaction
Figure 3 both shows how an increase in the SD of the covariate-treatment
interaction affects the MAE and posterior SD. The MAE increases as the
covariate-treatment interaction increases. The posterior SD increases as the
covariate-treatment interaction increases for the standard NMA model and
MAIC model, but stays relatively constant for the mixed AgD/IPD model
and the AgD model including the covariate. The top row shows the impact on
the indirect estimate of C versus A. At the left-hand side of the x-axis, when
the interaction is zero, the covariate is a prognostic variable rather than an
effect modifier. In this case both the MAIC models and the standard NMA
models are quite similar, while the mixed AgD/IPD model has a smaller
MAE. However, we should bear in mind that it can be difficult to distinguish
between prognostic variables and effect modifiers, and note that, in the case
of an anchored comparison, there is a larger benefit to adjusting for an effect
modifier than there is for not adjusting for a prognostic variable.
In the bottom row we examine the impact of the covariate-treatment
interaction on the direct estimate of B versus A. Although it is not necessary
to do an MAIC for this estimate, it is important to understand how this
estimate is affected by MAIC, as NMAs often report the relative efficacy
of all treatments versus the reference treatment. MAIC produces a slightly
lower MAE than the standard NMA model.
Finally, the graphs on the right hand side show the posterior SD. We
see a small increase in posterior SD due to an increase in the covariate-
treatment interaction for the standard NMA model and MAIC model, but
the increase is not as large as the increase for the MAE. The posterior SD
of the mixed AgD/IPD model and the AgD model with the covariate is
relatively unaffected by the covariate-treatment interaction.
16
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Figure 3: Examining mean absolute error (MAE) and posterior standard deviation
(SD) while increasing the SD of the covariate-treatment interaction. The dotted
lines around each MAE estimate represent the MC Error on each side. At the
left most point of the x-axis the covariate is a prognostic variable and at all other
points the covariate is an effect modifier. In general, the mixed AgD/IPD model
produces the most accurate estimate and smallest posterior SD, especially when
the interaction is large. Again, when the interaction is large, the MAIC model
produces a slightly lower MAE, but slightly higher posterior SD than the standard
NMA model. The standard NMA model with covariate produces a similar MAE
to the standard NMA model, but the posterior SD is much larger than the other
models.
From this simulation we see that the mixed AgD/IPD model is the most
appropriate model, while the AgD model with the covariate is clearly inferior
to the other models. Here we are including three extra terms in a model with
only four studies, and hence for the AgD model we do not have enough data-
points to include the extra terms. We should note that this model is already
using a much less vague prior for the covariate effect, in order to reduce
the uncertainty in the posterior SD, than it is for any other parameter. We
therefore do not explore the AgD model with covariate in further scenarios,
due to a preference for model simplicity.
These simulations use the same prevalence of the covariates that are in
17
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Figure 4: Examining mean absolute error (MAE) and posterior standard deviation
(SD) while varying the proportion of patients possessing each characteristic in the
BC-AgD study. The dotted lines around each MAE estimate represent the MC
Error on each side. The proportion of patients possessing each characteristic in
the IPD study is 40%, 50% and 60% for the three IPD-AB studies, respectively.
There is little difference between the models in the full network population for the
indirect C versus A estimate. In general, the mixed AgD/IPD model produces the
lowest MAE and posterior SD. For the target population the MAIC model produces
a lower MAE, however, the MAIC model also produces a higher posterior SD.
the ndMM network, so it can give us an indication of how MAIC may affect
our estimates in this network. However, we will now analyse other scenarios
to ascertain the benefits or drawbacks of MAIC over other networks.
3.1.2 Varying Proportion of Patients Possessing Each Covariate
Figures 4 and 5 show that the proportion of patients possessing the char-
acteristics associated with the covariates in each trial greatly influences the
effect of the various models. In both figures we see that for the target popu-
lation (centre graphs), MAIC produces an MAE which is mainly lower than
or the same as the corresponding standard NMA model. However, using a
mixed AgD/IPD model generally produces MAEs as low as, or lower than the
18
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Figure 5: Examining mean absolute error (MAE) and posterior standard deviation
(SD) while varying the proportion of patients possessing each characteristic in the
AB-IPD study. The dotted lines around each MAE estimate represent the MC
Error on each side. The proportion of patients possessing each characteristic in
the BC-AgD study is 50%. There is little difference between the MAIC vs standard
NMA in the full network population for the indirect C versus A estimate, while
the standard NMA model produces a lower MAE than the MAIC model in the full
network population for the direct B versus A estimate. For the target population the
MAIC model produces a lower MAE but a higher posterior SD than the standard
NMA model. Once again the mixed AgD/IPD model produces both the lowest MAE
and posterior SD.
MAIC model. For the target population, when the distribution of covariates
in the AB-IPD trials is very different to the BC-AgD trial (i.e. the extremes
of the graphs) the standard NMA model in general gives worse estimates
than it does when the covariate make-up is similar between the studies. The
MAIC model also has a flat line for the target population in Figure 5, but
has a slight concave downwards slope for the target population in Figure 4.
Looking at the effect of MAIC on the full network population (left hand
side graphs) and on the posterior SD (right hand side graphs) we can see
that there are downsides to running an MAIC. In Figure 5 the MAIC gives
a posterior SD that is at least as big, if not greater than, the standard NMA
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model for both the direct AB estimate and the indirect AC estimate. This
means we are increasing our uncertainty in our estimate by running an MAIC.
In particular, we can see that the C versus A posterior SD is much larger
than the corresponding MAE for the MAIC. We also see that the posterior
SD increases when more reweighting is required. The MAE of the C vs A
estimate for the full network population is quite similar for the standard
NMA model and the MAIC model. However, the direct B vs A estimate
from the MAIC in the full network population is usually worse, or at best
similar to the the standard NMA, hence we do not recommend using MAIC
for this estimate. The mixed AgD/IPD model generally produces the lowest
MAEs and posterior SDs.
There is a noticeable lack of symmetry in some models in Figures 4 and
5. This is due to the fact that the model is computed on the natural log
scale, and therefore the distances between points on the axis are not equal
on this scale.
As mentioned earlier, some of the models show a concave downwards
slope. For example direct B versus A estimate for the MAIC model in the
target population graph in Figure 4. In Figure 4 the MAIC reweights the
data such that the proportion possessing each characteristic is equal to the
number on the x-axis. The patients in the trial are most heterogeneous
when 50% of the patients in the trial possess each characteristic. This is
approximately where the model produces the worst MAE (slight difference
due to some calculations being on the natural log scale). This is consistent
with Figure 2 of Shrier et al21, where the estimated odds ratio is impacted
by the value of the covariate.
Figures 4 and 5 both assume that for any given point on the x-axis there
is the same proportion of patients who possess the characteristic associated
with each covariate in each trial, so it is not possible to differentiate between
the two methods of reweighting the IPD. We therefore consider an additional
scenario in where there is a difference between the proportion possessing the
characteristic associated with each covariate in each IPD trial. Given that the
purpose of this scenario is to compare the two MAIC methods, we exclude the
AgD/IPD model due to the large computing power required for this model.
Figure 6 keeps the overall proportion of patients who possess each char-
acteristic constant at 45%, while varying the IPD proportion between the
three studies. For example, on the left most point of the x-axis all three
AB-IPD studies have 45% of patients who possess each characteristic, how-
ever, on the right hand side Study 1 has 45% of patients who possess each
characteristic, Study 2 has 90% of patients who possess each characteristic,
and Study 3 has 10% of patients who possess each characteristic. We can see
overall that when there is an increase in heterogeneity between the studies
20
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Figure 6: Examining mean absolute error (MAE) and posterior standard deviation
(SD) while varying the difference in proportion possessing the characteristic asso-
ciated with each covariate between AB-IPD trials. The dotted lines around each
MAE estimate represent the MC Error on each side. On the left most point of the
x-axis all three AB-IPD studies have 45% of patients possessing the characteristic
associated with each covariate, however, on the right hand side Study 1 has 45%
of patients possessing the characteristic associated with each covariate, Study 2
has 90% of patients possessing the characteristic associated with each covariate,
and Study 3 has 10% of patients possessing the characteristic associated with each
covariate. The numbers on the x-axis represent the difference in the proportion
possessing the characteristic associated with each covariate between Study 2 and
Study 3. The AB-AgD study has a fixed proportion possessing the characteris-
tic associated with each covariate of 90%. MAIC pooled trials is a less stringent
requirement and so less reweighting needs to be done with this method.
the posterior SD increases. When the studies are similar there is not much
of a difference between the two reweighting methods. However, the MAIC
pooled trials method is a less stringent requirement, since the AB-IPD stud-
ies need only match the BC-AgD study between the three of them, whereas
for MAIC separate trials each AB-IPD study needs to match the BC-AgD
study. Therefore, less reweighting is carried out for the pooled trials method
than the separate trials method. Therefore, the separate trials method pro-
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duces a slightly smaller MAE in the target population, while the pooled trials
method produces a slightly smaller MAE in the full network population.
3.1.3 Coverage Probabilities and Fixed Effects Models
We compare the coverage for both RE and FE models in Figures 7, 8, 9, and
10. In general, the RE models had coverage which was closer to the nominal
95% CrI, and this is why we chose to present the further analysis on the
RE model only. It is worth noting, however, that FE models gave similar
results to the RE models for the MAE. The posterior SD, however, was much
smaller for the FE models compared to the RE models, which explains the
lower coverage.
In the target population we note that the MAIC models often had cov-
erage which was closer to the nominal 95% than the corresponding standard
NMA model. This is especially true for the FE models, which implies that
MAIC has reduced the differences between trials. However, we would stress
that in a real-world scenario, there may be more effect modifiers which have
not been accounted for.
The coverage probability is driven by a combination of the MAE and the
posterior SD. For example, the coverage probabilities for the standard NMA
models in Figure 9 is almost the inverse of the MAE in Figure 5. In this case
the MAE increases at the edges of the graphs, but the posterior SD stays
the same for the standard NMA model and the mixed AgD/IPD model. In
other cases, for example in Figure 10, we see the coverage of the standard
standard RE NMA models increase as the difference between the IPD, in
terms of the proportion of patients possessing the characteristic associated
with the covariate, increases. This is almost entirely due to an increase in
the posterior SD in Figure 6.
3.1.4 Effect on the Between Study Heterogeneity
Figure 11 shows how the between study heterogeneity is affected in the var-
ious scenarios explored previously. In many cases the models produce quite
similar between study heterogeneity. On the top left panel we can see that
the standard NMA model with the covariate (Model b.) produces larger
between study heterogeneity than the other models. This model often be-
haves differently from the other models, for example, the posterior SD of
this models was also higher than the other models in Figure 3. In the bot-
tom left panel we see that when the IPD trials have a relatively large or
small number of patients possessing the characteristic associated with each
covariate (i.e. at the edges of the graph), the MAIC model produces a larger
22
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Figure 7: Examining coverage probability while increasing the standard deviation
of the covariate-treatment interaction. The coverage of all models decreases as the
covariate-treatment interaction increases.
measure of heterogeneity then the standard NMA model, most likely due to
the large amount of reweighting required. In the bottom right panel we see
a clear increasing trend as the difference in proportion of patients possessing
the characteristic associated with each covariate increases between AB-IPD
trials. Hence, as the difference in each patient population increases, more
between trial heterogeneity is estimated, as the model does not explicitly
take the effect modifiers into account. The standard NMA model is more
affected by this difference. When the three IPD trials are similar the MAIC
models again produce a larger estimate of between study heterogeneity than
the standard NMA model. There is no noticeable difference between MAIC
pooled trials and MAIC separate trials model.
3.2 Applied Example in Newly Diagnosed Multiple Myeloma (ndMM)
We first investigate which covariates are appropriate to be used in the ndMM
network. Table 4 shows the potential bias resulting from the differences
between trials, assuming that there is an independent covariate-treatment
interaction. A second scenario was considered assuming an exchangeable
23
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Figure 8: Examining coverage probability while varying the proportion of patients
possessing the characteristic associated with each covariate in the BC-AgD study.
The FE models are more sensitive to differing values of patients possessing the
characteristic associated with each covariate than the RE models.
Table 4: Potential bias if each covariate is an effect modifier. This is based on
a fixed effects model using medians, using IPD where possible and assuming an
independent covariate-treatment interaction. The potential bias is calculated by
multiplying the absolute difference in interaction for Len versus Thal and the ab-
solute difference between the proportion of patients possessing the characteristic













Absolute Difference in Interaction for Len versus
Thal if Effect Modifier
0.24 0.26 0.31 0.01 0.31
Proportion possess-
ing characteristic
McCarthy (Len-Placebo) 0.58 0.24 0.66 NA 0.54
Attal (Len-Placebo) 0.64 0.20 0.59 0.13 0.57
Palumbo (Len-Placebo) 0.69 0.13 0.39 0.36 0.54
Average Len-Placebo 0.63 0.19 0.55 0.25 0.55
Morgan (Thal-Placebo) 0.58 0.34 0.74 0.42 0.64
Potential Bias if Effect Modifier 0.01 0.04 0.06 0.002 0.03
DIC Assuming Effect Modifier 8559 7623 7730 4150 8550
DIC Assuming Prognostic Variable 8560 7623 7728 4150 8551
DIC Assuming Both 8560 7623 7730 4150 8550
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Figure 9: Examining coverage probability while varying the proportion of patients
possessing the characteristic associated with each covariate in the AB-IPD study.
The FE models are more sensitive to differing values of patients possessing the
characteristic associated with each covariate than the RE models.
covariate-treatment interaction with similar results, and we therefore just
show the independent model. In both cases no covariate could be excluded
as not interacting with the treatments by looking at the differences in DIC.
We also found the potential bias in most cases to be relatively small. The only
exception to this was Response which had the highest potential bias of 0.10.
However, based on the DIC, Response was most likely to be a prognostic
variable, although the differences in the DIC was below the threshold of
3. Clinical advice recommended that gender was unlikely to interact with
treatment, so we excluded this as a covariate for matching, given that it also
had one of the smallest potential biases. We considered using the other four
covariates for matching. However, given that we did not have any information
on cytogenetics in the McCarthy trial, we would not have been able to include
this in a pooled trials model. Hence, to allow a equal comparison between
pooled trials MAIC and separate trials MAIC we excluded cytogenetics as a
covariate to be used in the MAIC. For a clinical analysis we could of course
include cytogenetics, but as our goal was to analyse the differences between
models we found it to be more appropriate to exclude it, given that it also
25
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Figure 10: Examining coverage probability while varying the difference in propor-
tion possessing the characteristic associated with each covariate between AB-IPD
trials. In general RE models have coverage closer to the nominal 95% probability
than FE models.
had the smallest potential biases. In the case of the models that explicitly
include a covariate (Models b. and e.), we included only the covariates for
response and ISS stage, as we had no age information for the Jackson trial.
We considered both FE and RE models. However, when comparing the
DIC between FE and RE for each of the five models shown in Table 5, we
found no differences greater than three, and therefore could not conclude
that one model was more appropriate than the other. We therefore present
the results of the RE model, as these, in general, had coverage which was
closer to the nominal 95% CrI in Section 3.1.3.
Figure 12 shows the results for the ndMM network. The point estimates
in all cases indicate that lenalidomide is superior to thalidomide. However,
the Credible Intervals (CrI) span zero. The relative size of the CrIs be-
tween models mainly replicate what we saw in the simulation study. The
standard NMA model with covariate and the mixed AgD/IPD model have
the widest CrIs. For the standard NMA model with covariate this repli-
cates what we saw in the simulation study. There are a few reasons why
26
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Figure 11: Effect on the between study heterogeneity. In the bottom left panel we
see that when the IPD trials have a relatively large or small number of patients
possessing the characteristic associated with each covariate (i.e. at the edges of
the graph), the MAIC model produces a larger measure of heterogeneity then the
standard NMA models, most likely due to the large amount of reweighting required.
In the bottom right panel we see a clear increasing trend as the difference in pro-
portion of patients possessing the characteristic associated each covariate increases
between AB-IPD trials. When the three IPD trials are similar the MAIC model
again produces a larger estimate of between study heterogeneity than the standard
NMA model.
Table 5: Estimate of between study heterogeneity for the random effects (RE)
model, and the difference in DIC for the Fixed Effects (FE) model minus the RE
model. Given that the difference in DIC is small, we conclude that there is not
enough evidence to conclude that either the RE or FE model fits better than the
other.
Between Study Heterogeneity Difference in DIC (RE minus FE)
HR Standard NMA (a) 0.15 1.58
HR MAIC With Cov (b) 0.41 0.63
HR MAIC Separate (c) 0.22 1.34
HR MAIC Pooled (d) 0.22 0.39
Mixed AgD/IPD (e) 0.31 -2.00
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Figure 12: Credible intervals (CrI) for the log hazard ratios for ndMM network.
The point estimates for lenalidomide are superior to thalidomide in all cases, how-
ever, the CrIs all cross the line of no effect at zero. MAIC does not have a large
impact on the point estimate but slightly increases the width of the credible inter-
vals.
the mixed AgD/IPD model may be larger in this example than in the sim-
ulation study. Firstly, in the simulation study the binary covariates had a
truly binary effect, whereas in this case a number of categories have been
grouped together. Secondly, in the simulation study the covariates were ef-
fect modifiers, whereas in this case we are uncertain if this covariates are
definitely effect modifiers. Thirdly, we have identified additional covariates
in the ndMM example, which we are unable to include in this model due to
lack of data, which was not the case in the simulation study.
We can also look at the between study heterogeneity for the RE models,
as shown in Table 5. The between study heterogeneity is lowest for the
standard NMA model, followed by the MAIC models, and is highest for the
model which explicitly include the covariate. This may indicate that there
are further unidentified covariates, which may be contributing to the between
study heterogeneity.
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4. Discussion
With MAIC generating more interest across the research and pharmaceutical
community, it is important to evaluate the benefits and drawbacks compared
to other models. While we saw some benefits to using MAIC over the stan-
dard NMA model, these benefits can be obtained by using a mixed AgD/IPD
NMA which doesn’t negatively impact the MAE in the full network popu-
lation, although it may lead to larger CrIs in reality than observed in the
simulation study. Our results and recommendations are summarised in Ta-
ble 6. We caution that while this conclusion hold true for our simulation
study, there may be other scenarios when the models behave differently, in
particular when some models are mis-specified.




C vs A Full network MAE is similar
for all models.
Don’t use MAIC.





Use mixed AgD/IPD model as main
analysis. Use MAIC only as a sensitiv-
ity analysis when interested in target
population.











Use mixed AgD/IPD model as main
analysis. Use MAIC only as a sensitiv-
ity analysis when interested in target
population.
We recommend that further analyses are carried out after conducting an
MAIC, such as an indication of model fit and the effective sample size of the
reweighted data. We also recommend that the results of the standard NMA
are presented as well, so that all researchers can assess the difference in results
between the two methods. A full list of considerations and recommendations
for reporting the results of MAIC can be found in Holmes et al22. A further
point to note is that the MAIC models generally produces posterior SDs that
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are larger than those produced from a standard NMA.
A limitation of this study is that we have considered binary covariates
only. The reason being is that the simulation study was motivated by the
real world ndMM example, where only binary covariates were available, thus
ensuring real world applicability. We note that it would have been preferable
to include more detailed information on the covariates in the ndMM example
as well, such as including the exact age of each patient rather than the
binary covariate of greater or less than sixty. For instance, Schmitz et al23
have noted the information lost when continuous outcomes are dichotomised.
Unfortunately, however, due to the difficulty involved in sharing IPD, only
binary covariates were available to us. An extension to the work could be to
include continuous covariates also.
In this work we carried out the NMA in a Bayesian setting. This can allow
for an extension of the three treatment network, as additional treatments and
trials can be included to extend the network, although a choice will have to
be made of which trial population(s) to match to.
In the simulation study we have assumed that all effect modifiers are
correctly identified, and we have accounted for them in the MAIC. However, a
further extension of this study could be to either have extra unidentified effect
modifiers, or to assess the impact of incorrectly assuming that a prognostic
variable is an effect modifier and using this in the MAIC as well. We touched
on this when the standard deviation of the covariate-treatment was zero, as
in this case the covariate is a prognostic variable, but we are treating it as if
it is an effect modifier. This could be explored further in future work. It is
important to note that strong justification should be given for the choice of
covariates used in an MAIC.
It is also important to note that the mixed AgD/IPD model may also
not perform as well in a real-world context, as this model is also likely to
be mis-specified in reality. However, we believe that the MAIC model is
more susceptible to mis-specification than the mixed AgD/IPD model, as the
mixed AgD/IPD model naturally gives very little weight to the covariates if
they’re not influential based on the data, whereas the MAIC is specified by
the researcher independently of the data.
In the ndMM example, results are quite similar with and without the
MAIC adjustment. However, by carrying out the MAIC it gives us increased
confidence in the result, as it shows that results hold across populations.
Were the results to have been quite contradictory, we would need to think
seriously about which population is more relevant to any decision problem at
hand, and also compare baseline differences between trials, to ascertain which
differences are most clinically notable. However, we wish to stress once again
that RCTs are the highest standard of evidence and post hoc adjustment of
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results cannot be a substitute for randomisation in clinical trials.
This work focuses on MAIC only. However, Simulated Treatment Com-
parison (STC)24,25 is another possible method of population adjusted when
IPD is available. A further extension of this work is to examine the suitabil-
ity of STC, and in particular, to identify circumstances when one of these
methods is more appropriate than the other.
MAIC can be much more susceptible to publication bias than a clinical
trial, since, in the authors’ experience, it rarely the case that an MAIC is
registered before it is carried out. While a standard NMA could also be
susceptible to the same publication bias, we note that Prospero provides a
facility to pre-specify NMAs. The authors searched for the terms “matching
adjusted indirect comparison”, “simulated treatment comparison”, “popula-
tion adjusted indirect comparison”, “MAIC”, and “STC” on Prospero on the
1st of July 2019 and found only one study which specifies the possibility of
carrying out an MAIC26, but even this study does not specify covariates on
which to adjust. MAICs are relatively easy to undertake, provided one has
the IPD, which is most likely owned by the manufacturer of the treatment.
If an MAIC has negative implications for the owner of the IPD, then there
is no obligation to publish the results. There is also a lot of flexibility for
the analysts to choose which covariates to adjust for, which gives greater
scope to choose covariates that may give better results for the owners of the
IPD treatment. It is a limitation of our simulation study that we cannot
explore such aspects here, though we do caution users of MAIC results on
the possibility of these potential biases.
We note, however, that there are benefits to the concept of MAIC, and
therefore suggest that it may be more appropriate to specify the exact ap-
proach of an MAIC or mixed AgD/IPD model at an earlier stage in the
process, before the researchers have seen the data. For example, if an inves-
tigator was in the process of carrying out a clinical trial, and was aware of
another trial which had a different patient population, they could pre-specify
the covariate adjustment in their statistical analysis plan before analysing the
data, which would allow more confidence in the results of the MAIC.
4.1 Conclusion
While MAIC can be beneficial as a sensitivity analysis to confirm results
across patient populations, we advise that MAIC is used and interpreted
with caution. Ideally, the covariate adjustment in an MAIC should be pre-
specified in a statistical analysis plan before analysing the data.
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8. Highlights
What is already known?:
• Given there is one trial with individual patient data (IPD) available,
and another trial with only aggregate data (AgD) available, Matching
Adjusted Indirect Comparison (MAIC) can be used to reweight patients
in the IPD trial so that the covariate make-up of the IPD trial matches
that of the AgD trial.
What is new?:
• We undertake a simulation study to compare MAIC to a standard NMA
or a standard NMA using a covariate term.
• We assess how to best reweight three IPD trials by using either an
MAIC pooled trials method or MAIC separate trials method.
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Potential impact for RSM readers outside the author’s field:
• (MAIC) is an increasingly popular technique and we provide guidance
on the appropriateness of its use in different scenarios.
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A. Appendix
Figure A1: Examining MAE and posterior SD while varying the proportion of
patients possessing each characteristic in the AB-IPD study. The baseline risk in
each study, the treatment effect and the overall covariate effect are simulated from
N(1.2, 0.7).
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Figure A2: Examining MAE and posterior SD while varying the proportion of
patients possessing each characteristic in the AB-IPD study. The baseline risk in
each study, the treatment effect and the overall covariate effect are simulated from
N(0.2, 0.1)
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Figure A3: Examining bias and standard error while increasing the standard devi-
ation of the covariate-treatment interaction
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Figure A4: Examining bias and standard error while varying the proportion of
patients possessing each characteristic in the BC-AgD study
39
This article is protected by copyright. All rights reserved.
Figure A5: Examining bias and standard error while varying the proportion of
patients possessing each characteristic in the AB-IPD study. The baseline risk in
each study, the treatment effect and the overall covariate effect are simulated from
N(1.2, 0.7).
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Figure A6: Examining bias and standard error while varying the proportion of
patients possessing each characteristic in the AB-IPD study. The baseline risk in
each study, the treatment effect and the overall covariate effect are simulated from
N(0.7, 0.4).
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Figure A7: Examining bias and standard error while varying the proportion of
patients possessing each characteristic in the AB-IPD study. The baseline risk in
each study, the treatment effect and the overall covariate effect are simulated from
N(0.2, 0.1).
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Figure A8: Examining bias and standard error while varying the difference in
proportion possessing the characteristic associated with each covariate between AB-
IPD trials
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